Cilastatin/imipenem/relebactam

Drug Profile

Cilastatin/imipenem/relebactam

Alternative Names: Cilastatin/relebactam/imipenem; IMI/REL; Imipenem/cilastatin/relebactam; Imipenem/relebactam/cilastatin; MK-7655A; Relebactam + imepenem/cilastatin; Relebactam/cilastatin/imipenem; Relebactam/imipenem/cilastatin

Latest Information Update: 28 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antibacterials; Azabicyclo compounds; Carbapenems; Cyclopropanes; Piperidines; Small molecules; Thienamycins
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors; Exopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Bacterial infections; Pneumonia
  • Phase I Gram-negative infections

Most Recent Events

  • 12 Jun 2017 Phase-I clinical trials in Gram-negative infections (In neonates, In infants, In children, In adolescents) in Colombia, Ukraine, USA (IV) (EudraCT2016-004328-43)
  • 28 Feb 2017 Merck has patent protection for cilastatin/relebactam/imipenem in USA (Merck Annual report 2016)
  • 20 Jun 2016 Interim efficacy and adverse events data from a phase II trial in bacterial infections released by Merck
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top